These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37426527)

  • 1. Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions.
    Ajufo E; Nayak A; Mehra MR
    JACC Basic Transl Sci; 2023 Jun; 8(6):720-727. PubMed ID: 37426527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the Win Ratio Analysis in Critical Care Trials.
    Monzo L; Levy B; Duarte K; Baudry G; Combes A; Ouattara A; Delmas C; Kimmoun A; Girerd N
    Am J Respir Crit Care Med; 2024 Apr; 209(7):798-804. PubMed ID: 38285595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.
    Dong G; Li D; Ballerstedt S; Vandemeulebroecke M
    Pharm Stat; 2016 Sep; 15(5):430-7. PubMed ID: 27485522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
    Pocock SJ; Ariti CA; Collier TJ; Wang D
    Eur Heart J; 2012 Jan; 33(2):176-82. PubMed ID: 21900289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of the win odds in the design of non-inferiority clinical trials.
    Peng L
    J Biopharm Stat; 2020 Sep; 30(5):941-946. PubMed ID: 32475213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
    Kotalik A; Eaton A; Lian Q; Serrano C; Connett J; Neaton JD
    Clin Trials; 2019 Dec; 16(6):626-634. PubMed ID: 31389723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The win ratio approach for composite endpoints: practical guidance based on previous experience.
    Redfors B; Gregson J; Crowley A; McAndrew T; Ben-Yehuda O; Stone GW; Pocock SJ
    Eur Heart J; 2020 Dec; 41(46):4391-4399. PubMed ID: 32901285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On recurrent-event win ratio.
    Mao L; Kim K; Li Y
    Stat Methods Med Res; 2022 Jun; 31(6):1120-1134. PubMed ID: 35345957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A win ratio approach to comparing continuous non-normal outcomes in clinical trials.
    Wang D; Pocock S
    Pharm Stat; 2016 May; 15(3):238-45. PubMed ID: 26970432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components.
    Liao R; Chakladar S; Gamalo M
    Pharm Stat; 2022 Nov; 21(6):1342-1356. PubMed ID: 35766113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The win odds: statistical inference and regression.
    Song J; Verbeeck J; Huang B; Hoaglin DC; Gamalo-Siebers M; Seifu Y; Wang D; Cooner F; Dong G
    J Biopharm Stat; 2023 Mar; 33(2):140-150. PubMed ID: 35946932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.
    Abdalla S; Montez-Rath ME; Parfrey PS; Chertow GM
    Contemp Clin Trials; 2016 May; 48():119-24. PubMed ID: 27080930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.
    Bebu I; Lachin JM
    Biostatistics; 2016 Jan; 17(1):178-87. PubMed ID: 26353896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust statistical inference for matched win statistics.
    Matsouaka RA
    Stat Methods Med Res; 2022 Aug; 31(8):1423-1438. PubMed ID: 35578578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjusting win statistics for dependent censoring.
    Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
    Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size formula for a win ratio endpoint.
    Yu RX; Ganju J
    Stat Med; 2022 Mar; 41(6):950-963. PubMed ID: 35084052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The stratified win ratio.
    Dong G; Qiu J; Wang D; Vandemeulebroecke M
    J Biopharm Stat; 2018; 28(4):778-796. PubMed ID: 29172988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the Win Ratio in Cardiovascular Trials.
    Ferreira JP; Jhund PS; Duarte K; Claggett BL; Solomon SD; Pocock S; Petrie MC; Zannad F; McMurray JJV
    JACC Heart Fail; 2020 Jun; 8(6):441-450. PubMed ID: 32466836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.
    Gasparyan SB; Buenconsejo J; Kowalewski EK; Oscarsson J; Bengtsson OF; Esterline R; Koch GG; Berwanger O; Kosiborod MN
    Ther Innov Regul Sci; 2022 Sep; 56(5):785-794. PubMed ID: 35699910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.